Decreased expression of Sirt1 is observed in various cancers such as GBM, bladder cancer, prostate cancer, ovarian cancer, and breast cancer, where it exerts its tumor-suppressive effects [27–29]. Here, SIRT1 is linked to prostate carcinoma.